NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva — Oct 18th, 2024

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva submitted an abbreviated new drug application seeking approval to sell a generic version of A...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? — Oct 17th, 2024

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals ...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B — Oct 21st, 2024

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years...

High Growth Tech Stocks to Watch in October 2024 — Oct 18th, 2024

The United States market has shown robust performance, climbing 1.1% in the last 7 days and rising 36% over the past year, with earnings anticipated to grow by 15% annually. In this promising environment, identifying high growth tech stocks involves looking for companies that demonstrate s...

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU — Oct 17th, 2024

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to t...